Skip to main content
ZYME
NASDAQ Life Sciences

Zymeworks Authorizes New $125M Share Repurchase Program, Extends Cash Runway Beyond 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$24.8
Mkt Cap
$1.763B
52W Low
$10.93
52W High
$29.75
52W Position info
127% above low
Off High info
17% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ZYME has more than doubled off its 52-week low of $10.93.

Summary

Zymeworks announced a new $125 million share repurchase program and extended its cash runway beyond 2028, leveraging existing cash and anticipated milestone payments.


Key Events · Financing and Capital Events · ZYME

  • New Share Repurchase Program Authorized

    The Board of Directors authorized a new 2026 share repurchase program, allowing the company to buy back up to $125.0 million of its common stock.

  • Previous Repurchase Program Terminated

    The prior 2025 program, which had repurchased 4,197,553 shares for $102.3 million at an average price of $24.36 per share, has been terminated.

  • Cash Runway Extended Beyond 2028

    The company expects existing cash as of March 31, 2026, combined with $440.0 million in anticipated regulatory milestone payments, to fund operations beyond 2028, even with full execution of the new repurchase program.


Analysis · ZYME · Life Sciences

Zymeworks has authorized a new $125 million share repurchase program, replacing a previous program that saw $102.3 million in repurchases. This substantial capital allocation strategy, representing over 7% of the company's market capitalization, signals management's confidence and commitment to returning capital to shareholders. Concurrently, the company provided updated cash runway guidance, projecting its existing cash and anticipated $440 million in regulatory milestone payments will fund operations beyond 2028. This extended runway provides significant financial stability, especially following a recent Q1 revenue miss, and addresses potential liquidity concerns, bolstering investor confidence in the company's long-term prospects.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZYME was trading at $24.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $10.93 to $29.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZYME - Latest Insights

ZYME
Nov 16, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $26.30
Real-time Price: $26.70 info
Change: +$0.400 (+2%) info
Market Cap: $1.869B info
ZYME
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $26.70 info
Change: -$4.11 (-13%) info
Market Cap: $1.869B info
ZYME
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $26.70 info
Change: -$4.11 (-13%) info
Market Cap: $1.869B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $26.70 info
Change: -$4.11 (-13%) info
Market Cap: $1.869B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $26.70 info
Change: -$1.85 (-6%) info
Market Cap: $1.869B info